ramipril
Following a limited submission
AWMSG advice
|
| Status: Recommended |
Ramipril oral solution is recommended as an option for use within NHS Wales for:
- Treatment of hypertension.
- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:
- manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease);
- diabetes with at least one cardiovascular risk factor.
- Treatment of renal disease:
- incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria;
- manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor;
- manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.
- Treatment of symptomatic heart failure.
- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.
|
|
|
Medicine details
|
| Medicine name |
ramipril |
| Formulation |
2.5 mg/5 ml oral solution |
| Reference number |
1639 |
| Indication |
- Treatment of hypertension.
- Reduction of cardiovascular morbidity and mortality in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or diabetes with at least one cardiovascular risk factor.
- Treatment of renal disease in patients with incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria or in patients with manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor or in patients with manifest glomerular non diabetic nephropathy as defined by macroproteinuria 3 g/day.
- Treatment of symptomatic heart failure.
- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction
|
| Company |
Rosemont Pharmaceuticals Ltd |
| BNF chapter |
Cardiovascular system |
| Submission type |
Limited |
| Status |
Recommended |
| Advice number |
2612 |
| NMG meeting date |
05/09/2012 |
| AWMSG meeting date |
17/10/2012 |
| Ratification by Welsh Government |
09/11/2012 |
| Date of issue |
13/11/2012 |
| Date of last review |
November 2022 |
Further information
This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |